We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
- Authors
Brugger, Wolfram; Triller, Nadja; Blasinska-Morawiec, Maria; Curescu, Stefan; Sakalauskas, Raimundas; Manikhas, Georgy Moiseevich; Mazieres, Julien; Whittom, Renaud; Ward, Carol; Mayne, Karen; Trunzer, Kerstin; Cappuzzo, Federico
- Abstract
The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended progression-free survival (PFS) and overall survival in patients with advanced non-small-cell lung cancer (NSCLC) who had nonprogressive disease following first-line platinum-doublet chemotherapy. This study included prospective analysis of the prognostic and predictive value of several biomarkers.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 31, p4113
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.31.8162